Drug Profile
Balugrastim - Teva Pharmaceutical Industries
Alternative Names: Albugranin; Albumin fused G-CSF; CG-10639; Egranli; G-CSF/albumin human - Teva; Long-acting Granulocyte Colony Stimulating Factor (G-CSF) - Teva; Neugranin; Pegfilgrastim biosimilar - TevaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator CoGenesys
- Developer Teva Pharmaceutical Industries
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Recombinant fusion proteins
- Mechanism of Action Granulocyte colony-stimulating factor replacements; Granulocyte stimulants; Haematopoiesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Submission Withdrawal Neutropenia
Most Recent Events
- 01 Jan 2015 Teva terminates phase II trial in Neutropenia (Chemotherapy-induced, In children, In adolscents) in USA, Bulgaria, Hungary, Romania, Russia, Ukraine, Poland, Georgia, Czech Republic and Slovakia (NCT01940601) prior to enrolment initiation
- 04 Nov 2014 Regulatory submission withdrawn for Neutropenia (Chemotherapy-induced) in European Union (SC)
- 26 Sep 2014 Preregistration for Neutropenia (Chemotherapy-induced) in European Union before September 2014 (SC)